T1	Participants 110 148	adults with major depressive disorder.
T2	Participants 349 393	atients with major depressive disorder (MDD)
T3	Participants 571 901	Adults aged 18-75 years with MDD (DSM-IV-TR) and Montgomery-Asberg Depression Rating Scale (MADRS) total score â‰¥ 26 were randomized (1:1:1) to receive vortioxetine 10 mg or 15 mg or placebo once daily, with the primary efficacy end point being change from baseline at week 8 in MADRS analyzed by mixed model for repeated measures.
